Market By Product, Application, Technology, End-user And Geography | Forecast 2019-2028
We provide additional customization based on your specific requirements. Request For Customization
The countries evaluated in the North American molecular point of care diagnostics market are:
•          Canada
•          The United States
The US government is providing funds to emerging start-ups for the development of the molecular diagnostics and precision medicine field. North America homes several well-established and developing firms that are working on creating new demonstrative tests. Additionally, the development of molecular diagnostic tests in the advanced biomarker field is offering employment opportunities across research facilities. These factors are likely to proliferate the growth of the molecular diagnostics point of care market in the region.
The easy approval of the drug-diagnostics related policies in the market has considerably fuelled the demand for molecular diagnostics in North America. Besides, other factors like the increasing aging populace and the growing prevalence of chronic disorders such as cancer, cardiovascular diseases and diabetes have contributed to the adoption of molecular diagnostics in the precision medicine market. Also, the advanced technologies, like companion diagnostics, NGS and liquid biopsy, have transformed the molecular diagnostics market.
The healthcare system in Canada is under immense pressure to adopt molecular diagnostics as it has become a critical part of the molecular point of care diagnostics. The rapid diagnostics nature of molecular diagnostics at low cost is also instigating the demand for the market. These factors are likely to contribute to regional growth in the coming years.
Quidel Corporation is a company that is involved in the development, manufacturing and marketing of diagnostic tests and pharmaceuticals across the world. Concerning the global molecular diagnostics point of care market, the company provides products like Solana Instrument and Solana assays. It has business operations majorly in four different segments, cardiac immunoassays, rapid immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The company has its headquarters in San Diego, California, the US.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1.  FDA ISSUED EMERGENCY USE AUTHORISATION DUE TO COVID 19 PANDEMIC
2.2.2.  INCREASED GERIATRIC POPULATION REQUIRES MORE DIAGNOSTIC SERVICES
2.2.3.  NORTH AMERICA REGION LEADS THE MARKET
2.2.4.  HYBRIDIZATION OF AVAILABLE TECHNOLOGIES IS A PROMISING TREND
2.3. PORTER’S FIVE FORCE ANALYSIS
2.3.1.  THREAT OF NEW ENTRANTS
2.3.2.  THREAT OF SUBSTITUTE
2.3.3.  BARGAINING POWER OF SUPPLIERS
2.3.4.  BARGAINING POWER OF BUYERS
2.3.5.  THREAT OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. REGULATORY FRAMEWORK
2.6.1.  UNITED STATES
2.7. MARKET DRIVERS
2.7.1.  DEMAND FOR DIAGNOSING PRESENCE OF SARS COV-2
2.7.2.  INCREASING DEMAND FOR NON-INVASIVE DIAGNOSIS
2.7.3.  RISE IN THE NUMBER OF DISEASES
2.8. MARKET RESTRAINTS
2.8.1.  HIGH CAPITAL REQUIREMENT
2.9. MARKET OPPORTUNITIES
2.9.1.  SPENDING ON RESEARCH & DEVELOPMENT
2.9.2.  INNOVATIONS IN THE MARKET
2.10. MARKET CHALLENGES
2.10.1. LACK OF HIGH COMPLEXITY TESTING CENTERS
3. NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK – BY PRODUCT
3.1. ASSAYS
3.2. INSTRUMENTS
3.3. SOFTWARE
4. NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY APPLICATION
4.1. INFECTIOUS DISEASE
4.1.1.  RESPIRATORY
4.1.2.  HOSPITAL-ACQUIRED INFECTIONS
4.1.3.  SEXUALLY-TRANSMITED INFECTIONS
4.1.4.  GASTROINTESTINAL INFECTIONS
4.2. ONCOLOGY
4.3. PRENATAL
4.4. OTHERS
5. NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY TECHNOLOGY
5.1. POLYMERASE CHAIN REACTION
5.1.1.  REAL-TIME PCR (Q-PCR)
5.1.2.  DIGITAL PCR (D-PCR)
5.2. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
5.3. OTHER
6. NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET OUTLOOK - BY END-USER
6.1. HOSPITAL
6.2. CLINICS
6.3. DIAGNOSTIC CENTERS
6.4. OTHERS
7. NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET – REGIONAL OUTLOOK
7.1. UNITED STATES
7.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT
8.2. ABACUS DIAGNOSTICA
8.3. BIOMERIEUX SA
8.4. BIOCARTIS
8.5. DANAHER
8.6. DIASORIN SPA
8.7. BIO-RAD LABORATORIES INC
8.8. F HOFFMANN-LA ROCHE LTD
8.9. LUMINEX CORPORATION
8.10. HOLOGIC INC
8.11. MESA BIOTECH
8.12. SPARTAN BIOSCIENCES INC
8.13. QUANTUMDX GROUP LTD
8.14. QUIDEL CORPORATION
8.15. QIAGEN
9. METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY
TABLE 1: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: EMERGENCY USE AUTHORISATION FOR DIAGNOSTICS BY FDA
TABLE 3: MARKET ATTRACTIVENESS INDEX
TABLE 4: VENDOR SCORECARD
TABLE 5: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (IN $ MILLION)
TABLE 6: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (IN $ MILLION)
TABLE 7: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
TABLE 8: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 9: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: COST COMPARISON BETWEEN LABORATORY, IMMUNOASSAY AND MOLECULAR POC DIAGNOSTIC TESTS
FIGURE 3: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ASSAYS, 2019-2028 (IN $ MILLION)
FIGURE 4: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INSTRUMENTS, 2019-2028 (IN $ MILLION)
FIGURE 5: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SOFTWARE, 2019-2028 (IN $ MILLION)
FIGURE 6: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)
FIGURE 7: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY RESPIRATORY, 2019-2028 (IN $ MILLION)
FIGURE 8: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL-ACQUIRED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SEXUALLY-TRANSMITTED INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GASTROINTESTINAL INFECTIONS, 2019-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ONCOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRENATAL, 2019-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REAL-TIME PCR (Q-PCR), 2019-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIGITAL PCR (D-PCR), 2019-2028 (IN $ MILLION)
FIGURE 17: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 18: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHER, 2019-2028 (IN $ MILLION)
FIGURE 19: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL, 2019-2028 (IN $ MILLION)
FIGURE 20: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY CLINICS, 2019-2028 (IN $ MILLION)
FIGURE 21: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIAGNOSTIC CENTERS, 2019-2028 (IN $ MILLION)
FIGURE 22: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 23: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2018 & 2028 (IN %)
FIGURE 24: UNITED STATES MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 25: CANADA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)